The median RFS was not reached (NR) with pembrolizumab (n = 487) vs 59.2 months (95% CI, 53.9-NR) with placebo (n = 489; HR, 0.65; 95% CI, 0.52-0.80). The 48-month RFS rates were 68.7% and 56.5%, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results